Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

Table 4 Adverse events necessitating discontinuation of infliximab therapy and adalimumab therapy

Adverse events necessitating discontinuation of infliximab therapy

Severe non-preexisting arthralgia with high anti-IFX antibody titer

IFX-induced linear IgA dermatosis after 3rd infusion

Epileptic seizure (first event) directly after start of 1st infusion

IFX-induced hepatitis

Severe non-preexisting arthralgia

Severe anaphylactic reaction

Severe anaphylactic reaction

Allergic reaction after 19 mo of therapy

Severe non-preexistent myalgia and arthralgia

Severe anaphylactic reaction

Adverse events necessitating discontinuation of adalimumab therapy

Generalized pruritus and exanthema, classified as allergic reaction

ADA-induced hepatitis

Acute absceding pyelonephritis

EBV-associated B-cell Hodgkin lymphoma, nodular-sclerosing type, stadium IIIB1

Frequent infections, especially of the upper respiratory tract

¹The patient had been under therapy with azathioprine for one year, subsequently with IFX for 19 mo, and then after a pause with ADA for 6 mo. IgA: Immunoglobulin A; ADA: Adalimumab; EBV: Epstein-Barr virus; IFX: Infliximab.